What Letram Treats: Main Uses and Benefits

Letram (Levetiracetam) is a therapy generally used for the long-term management of chronic seizure activity across a wide spectrum of epilepsy syndromes. The medication is relevant in clinical settings marked by recurrent and disruptive symptom manifestations and is relevant for easing the overall symptom load. Levetiracetam is utilized for specific seizure types as monotherapy or adjunctive therapy.

The medication helps provide supportive relief for symptoms related to heightened neurological activity. It is commonly used to help control the frequency and intensity of partial-onset (focal) seizures, myoclonic jerks, and primary generalized tonic-clonic seizures. This application in chronic conditions contributes to easing discomfort during periods of heightened symptoms.

“This medication is applied across therapeutic domains where additional symptomatic support is needed, assists with maintaining functional stability in conditions where functional stability becomes affected.”

Quick Fact: Relevance for Recurrent Seizure Activity

Letram is considered relevant for easing symptoms that cluster into patterns requiring supportive management, and is generally utilized as adjunctive (add-on) therapy for patients whose seizures are uncontrolled or refractory to other treatments. It may help patients cope more steadily with symptom fluctuations, which contributes to easing the overall symptom load.

Regulatory References

1. European Medicines Agency (EMA) overview

The official regulatory profile for Letram (Levetiracetam) defines strict population eligibility and use restrictions based on patient history, age, and physiological status.

Contraindications and Core Restrictions

Use of Letram is contraindicated in patients with a known hypersensitivity to levetiracetam or any component of the formulation. This represents the sole absolute prohibition for use established in regulatory documents.

Age-Specific Eligibility

The medicine is approved for adults and adolescents aged 16 years and older for both monotherapy and adjunctive therapy. Pediatric eligibility is tiered by seizure type: adjunctive use is permitted in children as young as one month old for partial-onset seizures, with varying minimum ages for other indications. Monotherapy use is not established in patients under 16 years of age.

Organ Function and Special Populations

Eligibility is conditional for patients with impaired renal function because the drug’s clearance is reduced by the kidneys, necessitating specific conditional use. Patients with severe hepatic impairment also require cautious consideration. During pregnancy, the drug may be used if considered clinically needed, though close drug level monitoring is required. Use during breastfeeding is not recommended by the manufacturer due to the drug’s excretion into human milk.

Interactions with other medicines and products

Letram (Levetiracetam) is characterized by government regulators as having a low potential for drug interactions, largely because its clearance does not rely extensively on the hepatic Cytochrome P450 (CYP450) enzyme system. Therefore, it does not significantly alter the plasma concentrations of many commonly co-administered medicines.

---

Documented Interaction Patterns

Interaction Type	Interacting Substance/Class	Official Outcome
Pharmacokinetic (Clearance)	Methotrexate	Reduced clearance of Methotrexate, leading to increased systemic exposure.
Pharmacodynamic (Additive)	CNS Depressants & Alcohol	Increased somnolence and sedation (additive CNS effects).
Metabolic (CYP450)	Oral Contraceptives	No significant alteration in the pharmacokinetics of Ethinyl Estradiol and Levonorgestrel.

---

The primary documented pharmacokinetic interaction involves Methotrexate, where co-administration results in reduced renal clearance for Methotrexate. This specific interaction is considered more relevant in patients with severe renal impairment due to the clearance mechanism. Furthermore, the official prescribing information notes a pharmacodynamic interaction with other Central Nervous System (CNS) depressants and Alcohol, which may intensify effects such as somnolence. Official labeling does not list any substances that are formally contraindicated for co-administration or require mandatory administration timing separation.

Letram's action is defined by a highly selective interaction within the brain, modulating neuronal network activity without relying on classic inhibitory pathways. The mechanism is independent of traditional targets like sodium channels or GABA receptors, generating a unique pharmacodynamic profile.

---

Targeting Synaptic Vesicle Protein 2A ( SV2A)

The core of Levetiracetam’s action involves high-affinity binding to the Synaptic Vesicle Protein 2A ( SV2A), a molecular structure found exclusively on neurotransmitter-containing vesicles in the presynaptic terminal. This binding event modulates the function of these vesicles, primarily limiting their capacity to release chemical messengers. This interaction ensures targeted pathway adjustment and contributes to the modulation of neuronal activity.

Modulating Presynaptic Release and Hyperexcitability

The functional consequence of SV2A modulation is the reduction of excessive, synchronized release of excitatory neurotransmitters, notably glutamate. By intervening at the presynaptic terminal, the drug limits the abnormal signaling that drives neuronal hyperexcitability and hypersynchronization, dampening the excessive electrical signaling in the Central Nervous System. This modulation results in a modulated state within targeted neural pathways, influencing the brain’s overall electrical dynamics.

How Letram is Used

Letram (Levetiracetam) is administered according to specific clinical protocols. The medication is generally intended for long-term therapy, and use is structured around a twice-daily schedule and mandatory dose adjustments for certain patient populations.

---

Official Administration Protocols

Instruction Domain	General Protocol
Route of Administration	Primary: Oral (tablets/solution). Temporary alternative: Intravenous (IV) infusion administered over 15 minutes.
Standard Adult Dosing	Treatment starts at 1000 mg/ day (500 mg twice daily). The dose is then increased (titrated) by 1000 mg/ day increments, typically every two weeks, up to a maximum recommended daily dose of 3000 mg.
Administration Conditions	The oral form may be taken with or without food. When switching between oral and IV forms, the total daily dose and frequency must remain equivalent.
Dose Adjustments	Dose reduction is necessary for patients with impaired renal function, with the regimen individualized based on estimated Creatinine Clearance (CLcr). For end-stage renal disease patients on dialysis, a supplemental dose is recommended after each dialysis session.

Research Evidence / Overview of Studies for Letram

Evidence for Partial-Onset (Focal) Seizures

The evidence base for Letram focuses on studies for focal seizures, which are conditions characterized by fluctuating or episodic manifestations. Initial evaluation involved short-term, randomized controlled trials (RCTs), many of which were double-blind and compared the study drug against a placebo or an inactive substance. These trials were used in research exploring how symptoms change over a defined time interval, and primarily included adults in individuals whose seizure activity was not fully controlled by other treatments, according to study protocols.

These studies monitored outcomes related to episodic or acute changes. Studies report how symptoms evolved in the observed populations, describing patterns observed in the groups that were administered the study drug compared to the placebo groups. Studies monitored outcomes related to physical discomfort, specifically tracking the median percentage reduction in seizure frequency and the proportion of study participants measured against the 50% seizure frequency reduction endpoint (Responder Rate). Further research examined the use of Letram as a single therapy in newly diagnosed adults, with studies exploring outcomes related to physical discomfort that involved other established treatments as comparators.

---

Evidence for Primary Generalized Tonic-Clonic and Myoclonic Seizures

Letram was also evaluated in studies examining its use as an add-on therapy for generalized seizure types. Placebo-controlled trials were conducted during periods of increased symptom activity for Primary Generalized Tonic-Clonic Seizures (PGTCS). These studies monitored outcomes describing episodic or acute changes, specifically focusing on the frequency of the most severe seizure episodes across children (age four and older), adolescents, and adults. Studies report patterns related to the monitored seizure frequency and the proportion of participants whose seizure frequency was reduced.

Separately, research examined the study drug's use for Myoclonic Seizures, primarily in adolescents and adults. These studies were used in research exploring short-term changes in the frequency of myoclonic seizure days. Studies monitored outcomes describing episodic or acute changes. The findings describe patterns observed in these specific study populations.

---

Long-Term Data and What is Still Uncertain

Beyond the initial short-term controlled studies, the evidence base includes non-comparative open-label extension studies. These studies involved participants who completed the original controlled trials and were observed over several years, providing extended observation of the patterns related to seizure control measurements over long periods. However, these open-label studies do not include a placebo group for comparison. Therefore, evidence is limited and heterogeneous regarding the long-term observation of outcomes when compared in a strictly controlled manner over many years. Comparative evidence is lacking for direct, controlled assessment against all other established antiepileptic drugs, particularly for long-term use as a single therapy. Finally, results apply only to the populations studied, and data for certain groups, such as very young children (infants) or older adults, remain insufficient or still emerging.

Key Studies & References

1. Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy
2. A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of The Safety And Efficacy Of Levetiracetam (Ucb L059) In Children With Epilepsy (NCT00150709)

Common questions about Letram (FAQ)

Q: What are the most common side effects of Letram that people talk about online?

Official product information describes the most frequently reported effects (classified as Very Common, meaning ge 10% of patients) as somnolence (sleepiness), headache, and fatigue or asthenia (a loss of strength or energy).

Nervous system and psychiatric effects, such as hostility and irritability, are also commonly documented in the official labeling.

Q: Is it common to feel tired when starting Letram?

Official safety information indicates that feeling tired (fatigue or asthenia) and somnolence (sleepiness) are classified as Very Common effects.

Regulatory documents also note that certain behavioral and psychiatric effects may be observed more frequently when treatment is first initiated or during the dose adjustment period.

Q: Can Letram cause weight changes?

Weight loss has been observed as an adverse reaction, as noted in regulatory documentation.

This observation is listed in official reports alongside other side effects.

Q: Does Letram affect sleep patterns?

Sleep-related effects are documented in official safety information.

Adverse reactions listed include somnolence (sleepiness), hypersomnia (excessive sleepiness), and insomnia (difficulty sleeping), which may influence sleep patterns.

Q: Is it necessary to take Letram every day?

The medication is typically prescribed on a continuous, twice-daily schedule, as it is generally intended for long-term therapy for the chronic management of seizures.

This continuous schedule is used to maintain consistent levels.

Q: Can Letram affect my ability to drive?

Official information advises caution regarding driving or operating machinery because the medicine may cause effects such as dizziness, drowsiness, or fatigue.

This is noted in the Warnings and Precautions section of the regulatory labeling.

Q: Are there any specific foods or drinks to avoid while using Letram?

Regulatory documents state that the oral form can be taken with or without food.

Official prescribing information does not list any specific food or non-alcoholic beverage restrictions.

Q: Is Letram considered a controlled substance?

Letram (Levetiracetam) is classified as a prescription-only medicine (Rx) by regulatory bodies.

It is not designated as a controlled substance by U.S. regulatory agencies, such as the DEA.

Q: What happens if I forget to use a dose of Letram?

The guidance for a missed dose is generally outlined in patient information.

This information advises against taking a double dose to make up for a single missed dose.

Q: Can I stop taking Letram if I feel better?

Official labeling advises that antiepileptic drugs should be withdrawn gradually.

This is described as minimizing the potential for an increase in seizure frequency.

Q: Does Letram have a withdrawal effect if stopped suddenly?

Official labeling states that antiepileptic drugs, including this medicine, should be withdrawn gradually.

This gradual approach is described as minimizing the potential for an increased frequency of seizures.

Q: Is there a possibility of an allergic reaction to Letram?

Official labeling lists hypersensitivity to the active substance or any component of the formulation as a contraindication.

Furthermore, rare but severe allergic-type skin reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are documented as possible serious adverse reactions.

Q: Is it true that Letram is only for short-term use?

Official regulatory information describes the medication as generally intended for long-term, chronic management of certain seizure types.

Q: Can Letram be crushed or cut?

Official administration instructions state that immediate-release tablets should generally be swallowed whole.

Some scored formulations may be broken.

Q: Can Letram cause an increase in blood pressure?

Official regulatory labeling includes an increase in blood pressure as an adverse reaction that has been reported.

This observation is noted in the safety warnings.

Q: Are there special warnings for people who are allergic to certain ingredients?

Regulatory documents describe the importance of informing healthcare professionals about all known allergies.

This includes sensitivities to foods, dyes, or preservatives that may be present in the formulation.

Q: Are there different strengths of Letram available?

According to official product information, the film-coated tablets are typically available in 250 mg, 500 mg, 750 mg, and 1000 mg strengths.

An oral solution and an intravenous injection are also available to facilitate different administration needs.

How to Store and Dispose of Levetiracetam (Letram)

Storage Conditions

Leteviracetam tablets and oral solution require storage at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be protected from light and kept away from excessive moisture, remaining in its original container until use. Storage environments must adhere to the rule of do not freeze.

Stability and Handling

For the intravenous concentrate, once diluted for infusion, the solution has a time-limited stability and should be used or discarded within 4 hours if stored at room temperature. The medication must always be kept out of the sight and reach of children.

Disposal Requirements

Disposal of unused or expired product, including any leftover intravenous solution, must be carried out in accordance with local regulations. Official guidelines prohibit the disposal of this medicine via wastewater or household garbage.